---
schema_version: "secwatch.filing_event.v1"
accession: "0001062993-25-002033"
form_type: "8-K"
ticker: "MDCX"
cik: "0001997296"
company_name: "Medicus Pharma Ltd."
filed_at: "2025-02-11T23:59:59+00:00"
generated_at: "2026-05-26T23:32:07.591623+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Medicus Pharma enters $15M equity purchase agreement with Yorkville; plans TSXV delisting

## Summary
- Standby Equity Purchase Agreement with Yorkville for up to $15M over 36 months; shares sold at 97% of market price.
- Proceeds to fund Phase 2 BCC trial, expand to pivotal trial and other non-melanoma skin diseases.
- Yorkville received $25k structuring fee and 105,840 commitment shares.
- Board approved voluntary delisting from TSXV; shares continue on Nasdaq (MDCX).
- Drawdowns require effective SEC registration statement; 19.99% cap and 4.99% beneficial ownership limit apply.

## SEC filing metadata
- accession: 0001062993-25-002033
- form_type: 8-K
- ticker: MDCX
- cik: 0001997296
- company_name: Medicus Pharma Ltd.
- filed_at: 2025-02-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1997296/000106299325002033/0001062993-25-002033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1997296/000106299325002033/form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001062993-25-002033
- JSON: https://secwatch.observer/filing/0001062993-25-002033.json
- Plain text: https://secwatch.observer/filing/0001062993-25-002033.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.